Biopsy Needles Market Size, Share, Growth, and Industry Analysis, By Type (Fully Automatic, Semi-Automatic), By Application (Hospitals, Clinics, Ambulatory Surgical Centres, Other), Regional Insights and Forecast to 2035

Biopsy Needles Market Overview

The global Biopsy Needles Market size estimated at USD 1043.08 million in 2026 and is projected to reach USD 1803.62 million by 2035, growing at a CAGR of 6.27% from 2026 to 2035.

The Biopsy Needles Market is expanding due to increasing demand for minimally invasive diagnostic procedures, rising cancer screening activities, and advancements in precision biopsy technologies. Biopsy needles are widely used for tissue sampling in oncology, urology, breast diagnostics, and image-guided procedures. In 2024, more than 19 million new cancer cases were estimated globally, increasing the requirement for accurate biopsy solutions. Core needle biopsy, fine needle aspiration, and vacuum-assisted biopsy procedures are gaining adoption due to improved accuracy and reduced patient discomfort. The Biopsy Needles Market Research Report highlights growing preference for disposable biopsy devices, automated needle systems, and advanced imaging-compatible products across healthcare facilities.

The USA biopsy needles market is supported by increasing diagnostic procedures, advanced healthcare infrastructure, and rising cancer detection programs. In 2024, the United States recorded more than 2 million new cancer cases, creating strong demand for biopsy technologies. Over 60% of breast cancer diagnoses in the country involve image-guided biopsy procedures, increasing adoption of core biopsy needles and vacuum-assisted devices. More than 70% of hospitals and diagnostic centers use minimally invasive biopsy techniques to improve patient outcomes. Growing investments in precision medicine, artificial intelligence-assisted imaging, and outpatient diagnostic procedures are further strengthening the USA Biopsy Needles Market Outlook.

Download Free Sample to learn more about this report.

Key Findings

• Market Size & Growth: The Biopsy Needles Market is witnessing strong adoption, with more than 65% of diagnostic centers globally incorporating advanced biopsy needle systems for cancer and tissue analysis procedures.
• Key Market Driver: Rising cancer screening demand contributes nearly 70% of biopsy procedure growth, while minimally invasive techniques influence around 60% of healthcare providers’ adoption decisions globally.
• Major Market Restraint: High device costs impact approximately 35% of healthcare facilities, while limited access to advanced biopsy technologies affects nearly 30% of developing healthcare markets.
• Emerging Trends: Disposable biopsy needles account for nearly 55% adoption preference, while image-guided biopsy technologies represent around 65% of newly installed diagnostic procedure systems.
• Regional Leadership: North America contributes approximately 40% of global biopsy needle adoption, while Europe represents nearly 30% due to advanced cancer diagnosis infrastructure.
• Competitive Landscape: Leading manufacturers focus on product innovation, with approximately 50% of companies investing in automated biopsy systems and precision diagnostic technologies.
• Market Segmentation: Core needle biopsy products hold nearly 60% market preference, while breast, prostate, and lung biopsy applications collectively represent more than 70% of total clinical usage.
• Recent Development: Around 45% of manufacturers introduced improved biopsy needle designs during 2023–2024, focusing on enhanced accuracy, reduced trauma, and compatibility with imaging systems.

Biopsy Needles Market Latest Trends

The Biopsy Needles Market Trends are strongly influenced by increasing adoption of image-guided biopsy procedures, technological improvements, and demand for faster diagnostic outcomes. In 2024, more than 65% of biopsy procedures used ultrasound, CT, or MRI guidance to improve tissue sampling accuracy. Vacuum-assisted biopsy systems are gaining popularity, with adoption increasing across more than 50% of specialized diagnostic centers. Manufacturers are focusing on lightweight needle designs, ergonomic handles, and automated firing mechanisms to improve procedural efficiency.

Another major trend in the Biopsy Needles Market Analysis is the rising use of disposable biopsy devices, which represent nearly 55% of healthcare provider preferences due to infection control advantages. Oncology applications contribute more than 60% of biopsy needle utilization as early cancer detection becomes a global healthcare priority. Increasing adoption of outpatient biopsy procedures, advanced imaging technologies, and precision medicine approaches is creating significant Biopsy Needles Market Opportunities for manufacturers and healthcare technology providers.

Biopsy Needles Market Dynamics

DRIVER

"Increasing Demand for Minimally Invasive Diagnostic Procedures"

The primary driver of the Biopsy Needles Market Growth is the rising demand for minimally invasive diagnostic procedures across oncology, breast cancer screening, and organ-specific disease detection. More than 70% of healthcare facilities globally are adopting minimally invasive biopsy methods to improve patient safety and diagnostic efficiency. Increasing cancer screening programs have accelerated the use of biopsy needles, with oncology applications accounting for nearly 60% of total biopsy device utilization. 

RESTRAINTS

"High Cost of Advanced Biopsy Technologies"

A major restraint affecting the Biopsy Needles Market Outlook is the high cost associated with advanced biopsy devices, automated systems, and imaging-compatible needle technologies. Nearly 35% of healthcare facilities in developing regions face budget limitations when adopting advanced biopsy equipment. Disposable biopsy needles, while improving infection control, increase procedural expenses compared with reusable alternatives. 

OPPORTUNITY

"Expansion of Precision Medicine and Advanced Diagnostic Technologies"

The Biopsy Needles Market Opportunities are increasing due to the expansion of precision medicine, personalized healthcare, and advanced diagnostic imaging solutions. More than 65% of newly developed diagnostic workflows integrate image-guided technologies to improve biopsy accuracy. Rising investments in cancer research and early detection programs are creating demand for next-generation biopsy needles with improved targeting capabilities. 

CHALLENGE

"Complex Regulatory Requirements and Product Standardization Issues"

The Biopsy Needles Market Challenges include complex regulatory approvals, product standardization requirements, and increasing competition among medical device manufacturers. More than 50% of biopsy needle manufacturers invest significantly in quality testing and compliance procedures before introducing new products. Differences in regulatory standards across countries can delay product launches and market expansion. Healthcare providers also require consistent product performance, safety validation, and compatibility with advanced imaging systems. 

Biopsy Needles Market Segmentation

The Biopsy Needles Market Segmentation is categorized based on product type and clinical application, with increasing adoption of advanced biopsy technologies across hospitals, diagnostic centers, and specialty clinics. By type, biopsy needles are mainly classified into fully automatic and semi-automatic systems. By application, these devices are used extensively in oncology, breast biopsy, prostate biopsy, liver biopsy, kidney biopsy, and other diagnostic procedures. More than 60% of biopsy procedures globally rely on core needle technologies. 

Download Free Sample to learn more about this report.

BY TYPE

Fully Automatic: Fully automatic biopsy needles represent one of the fastest-adopting segments within the Biopsy Needles Market due to their ability to provide controlled, rapid, and precise tissue sampling procedures. These systems are designed with automated firing mechanisms that improve needle deployment speed, reduce procedural variability, and enhance operator efficiency. More than 55% of advanced diagnostic facilities prefer automated biopsy technologies because they support consistent sample collection and reduce manual intervention. Fully automatic biopsy needles are widely used in breast, prostate, liver, and soft tissue biopsy procedures where accuracy is a critical requirement. Over 65% of image-guided biopsy procedures benefit from automated systems integrated with ultrasound, CT, or MRI imaging technologies. The growing focus on early cancer detection has increased demand for fully automatic devices, especially in specialized oncology centers. 

Semi-Automatic: Semi-automatic biopsy needles continue to maintain strong demand in the Biopsy Needles Market due to their affordability, reliability, and suitability for a wide range of diagnostic applications. These devices provide healthcare professionals with greater manual control while maintaining improved accuracy compared with conventional biopsy techniques. Nearly 45% of healthcare facilities globally utilize semi-automatic biopsy systems because they offer a balance between operational efficiency and cost management. Semi-automatic biopsy needles are commonly used in hospitals, diagnostic laboratories, and outpatient centers for procedures involving breast lesions, liver abnormalities, prostate evaluation, and soft tissue analysis. Approximately 50% of biopsy procedures in emerging healthcare markets rely on semi-automatic systems due to easier availability and lower operational requirements. 

BY APPLICATION

Hospitals: Hospitals represent the largest application segment in the Biopsy Needles Market due to the high volume of diagnostic procedures performed for cancer detection, organ evaluation, and disease monitoring. Hospitals account for more than 60% of biopsy needle utilization globally because they provide advanced imaging facilities, specialized medical professionals, and comprehensive diagnostic services. Biopsy needles are extensively used in hospital oncology departments, radiology units, pathology laboratories, and surgical departments for breast, prostate, liver, lung, and kidney tissue sampling. More than 70% of complex image-guided biopsy procedures are conducted in hospitals due to access to ultrasound, CT, and MRI technologies. The increasing number of cancer screening programs has significantly increased hospital demand for precision biopsy devices. 

Clinics: Clinics are an emerging application area in the Biopsy Needles Market as outpatient diagnostic procedures become more widely accepted across healthcare systems. Specialty clinics, including oncology clinics, breast diagnostic centers, and imaging clinics, are increasingly adopting biopsy needle technologies for faster and less invasive diagnosis. Clinics account for approximately 20% of biopsy needle usage due to growing demand for same-day diagnostic procedures and specialized healthcare services. More than 50% of outpatient biopsy procedures are performed in specialized clinics equipped with ultrasound-guided systems. Clinics prefer lightweight, easy-to-use biopsy needles that allow physicians to perform accurate tissue sampling with minimal patient discomfort. 

Ambulatory Surgical Centres: Ambulatory Surgical Centres (ASCs) are becoming an important application segment in the Biopsy Needles Market due to the increasing shift toward outpatient surgical and diagnostic procedures. These centres focus on providing efficient healthcare services with reduced patient recovery time and lower procedural complexity. ASCs contribute nearly 15% of biopsy needle demand as more patients choose minimally invasive procedures outside traditional hospital settings. Biopsy needles used in ambulatory centres support breast biopsy, soft tissue biopsy, and image-guided sampling procedures performed without extended hospitalization. More than 55% of ASCs equipped with advanced imaging technologies provide biopsy-related diagnostic services. 

Other Applications: Other applications in the Biopsy Needles Market include research institutions, diagnostic laboratories, academic medical centers, and specialized healthcare facilities. These applications contribute approximately 5% to 10% of overall biopsy needle utilization while supporting medical research, clinical studies, and specialized diagnostic procedures. Research centers use biopsy needles for tissue analysis, biomarker studies, and development of advanced diagnostic approaches. More than 40% of medical research facilities involved in oncology and pathology studies utilize biopsy technologies for sample collection and analysis. Diagnostic laboratories are adopting advanced biopsy systems to support accurate pathological evaluation and molecular testing. 

Biopsy Needles Market Regional Outlook

The Biopsy Needles Market Regional Outlook indicates strong adoption across developed and emerging healthcare markets due to increasing diagnostic procedures, cancer screening initiatives, and advancements in minimally invasive biopsy technologies. North America holds the leading position with approximately 40% of the global market share, supported by advanced healthcare infrastructure and high adoption of image-guided biopsy systems. Europe accounts for nearly 30% market share due to strong oncology research, established diagnostic networks, and rising demand for precision medicine. 

Download Free Sample to learn more about this report.

NORTH AMERICA

North America represents the largest regional segment in the Biopsy Needles Market, accounting for approximately 40% of the global market share due to advanced healthcare infrastructure, high diagnostic procedure volumes, and strong adoption of minimally invasive technologies. The United States contributes nearly 35% of global biopsy needle demand, supported by increasing cancer screening programs, advanced imaging facilities, and widespread availability of specialized diagnostic centers. More than 70% of major healthcare institutions in North America utilize image-guided biopsy procedures involving ultrasound, CT, or MRI technologies. The region has a strong presence of automated and disposable biopsy needle adoption, with nearly 60% of healthcare providers preferring advanced systems for improved accuracy and infection control. Canada contributes around 5% of the regional share due to expanding oncology services and increasing investment in diagnostic healthcare infrastructure. Hospitals and ambulatory surgical centers remain major users, representing over 75% of regional biopsy needle applications. The Biopsy Needles Market Analysis highlights that North America maintains leadership through continuous technological innovation, precision medicine adoption, and increasing demand for early disease detection solutions. 

EUROPE

Europe holds approximately 30% share of the global Biopsy Needles Market, supported by strong healthcare systems, increasing cancer diagnosis activities, and rising adoption of advanced biopsy technologies. Countries across Western Europe have high utilization of image-guided biopsy procedures, with more than 65% of specialized diagnostic centers using ultrasound-assisted or CT-guided biopsy techniques. Germany, the United Kingdom, France, and Italy represent major contributors to regional demand due to developed medical infrastructure and increasing investments in oncology diagnostics. The European market is influenced by growing adoption of disposable biopsy needles, which account for nearly 55% preference among healthcare professionals due to improved safety standards. Hospitals and diagnostic clinics contribute more than 70% of biopsy needle applications across the region. Increasing focus on personalized medicine and molecular diagnostics is encouraging healthcare providers to adopt high-precision biopsy systems. Germany contributes nearly 10% of global market share, while the United Kingdom represents around 7% due to strong cancer screening initiatives. 

GERMANY Biopsy Needles Market

Germany is one of the leading European markets for biopsy needles, representing approximately 10% of the global Biopsy Needles Market share. The country’s strong healthcare infrastructure, advanced hospital network, and increasing focus on early cancer diagnosis support widespread adoption of biopsy technologies. More than 65% of specialized diagnostic facilities in Germany utilize image-guided biopsy procedures for oncology and tissue analysis applications. Hospitals and medical centers across the country are increasingly adopting automated biopsy systems to improve accuracy and procedural efficiency. Breast, prostate, and liver biopsy procedures represent major application areas, accounting for more than 70% of biopsy needle usage in Germany. The growing emphasis on precision medicine and personalized treatment approaches is increasing demand for advanced tissue sampling solutions. German healthcare providers also show strong preference for disposable biopsy devices due to strict infection prevention standards. 

UNITED KINGDOM Biopsy Needles Market

The United Kingdom Biopsy Needles Market represents approximately 7% of the global market share, supported by increasing cancer screening activities, advanced healthcare services, and growing adoption of minimally invasive diagnostic procedures. The country has a well-established healthcare network with strong demand for biopsy needles in hospitals, diagnostic clinics, and specialized oncology centers. More than 60% of advanced diagnostic facilities in the United Kingdom utilize image-guided biopsy methods to improve tissue sampling accuracy. Breast cancer diagnosis, prostate evaluation, and soft tissue analysis are among the major applications driving biopsy needle demand. The adoption of disposable biopsy needles is increasing, with nearly 55% of healthcare providers preferring single-use devices for improved safety and infection control. Rising investment in precision diagnostics and personalized healthcare is encouraging medical facilities to adopt advanced biopsy systems. The United Kingdom market continues to benefit from technological advancements, increasing awareness of early disease detection, and growing demand for efficient outpatient diagnostic procedures.

ASIA-PACIFIC

The Asia-Pacific Biopsy Needles Market is expanding steadily and accounts for approximately 22% of the global market share due to increasing healthcare infrastructure development, rising cancer diagnosis rates, and growing adoption of minimally invasive diagnostic procedures. Countries including China, Japan, India, South Korea, and Australia are contributing significantly to regional demand through improvements in medical technology and diagnostic accessibility. More than 55% of major hospitals in developed Asia-Pacific economies are adopting advanced biopsy systems supported by ultrasound, CT, and MRI guidance. The region is witnessing increased demand for core needle biopsy and vacuum-assisted biopsy devices, with oncology applications representing nearly 60% of total usage. Japan and China together contribute more than 60% of the regional biopsy needle demand due to their advanced healthcare systems and large patient populations. Emerging economies in Asia-Pacific are improving diagnostic capabilities, with approximately 45% of healthcare facilities expanding investments in tissue sampling technologies. 

JAPAN Biopsy Needles Market

Japan represents a significant market in the Asia-Pacific Biopsy Needles Market, contributing approximately 8% of the global market share due to advanced healthcare infrastructure, strong medical technology adoption, and increasing demand for cancer diagnosis solutions. The country has a high adoption rate of image-guided biopsy procedures, with more than 70% of specialized diagnostic centers using ultrasound or CT-assisted biopsy techniques. Japan’s aging population and increasing focus on early disease detection are major factors driving demand for advanced biopsy needle systems. Breast, prostate, and liver biopsy applications account for more than 65% of biopsy needle utilization across Japanese healthcare facilities. Hospitals and specialized diagnostic centers are increasingly adopting disposable biopsy needles to improve infection control and procedural safety. More than 60% of healthcare providers in Japan prefer precision biopsy devices that support accurate tissue collection. The country’s focus on robotics, medical automation, and advanced diagnostic technologies is encouraging the development and adoption of next-generation biopsy solutions. Growing investments in personalized medicine and oncology research continue to strengthen the Japan Biopsy Needles Market position.

CHINA Biopsy Needles Market

China holds a major position in the Asia-Pacific Biopsy Needles Market, accounting for approximately 10% of the global market share due to its large patient population, expanding healthcare infrastructure, and increasing demand for cancer diagnostic procedures. The country has witnessed significant growth in biopsy needle adoption as healthcare facilities improve access to advanced diagnostic technologies. More than 60% of tertiary hospitals in major Chinese cities utilize image-guided biopsy systems for oncology and tissue analysis procedures. Rising cancer screening initiatives have increased demand for core needle biopsy and vacuum-assisted biopsy technologies. Breast, lung, liver, and prostate diagnostic applications represent more than 70% of biopsy needle usage in China. Healthcare providers are increasingly adopting automated and disposable biopsy devices to improve accuracy and reduce procedural risks. Approximately 50% of healthcare facilities in urban areas are upgrading diagnostic equipment with advanced biopsy solutions. 

MIDDLE EAST & AFRICA

The Middle East & Africa Biopsy Needles Market accounts for approximately 8% of the global market share, supported by improving healthcare infrastructure, rising awareness about cancer diagnosis, and increasing investments in medical facilities. Countries such as Saudi Arabia, United Arab Emirates, South Africa, and Egypt are contributing to regional demand through expansion of hospitals, diagnostic centers, and specialized oncology facilities. More than 45% of leading healthcare centers in developed Middle Eastern countries have adopted image-guided biopsy technologies to improve diagnostic accuracy. Oncology applications represent nearly 60% of biopsy needle usage in the region due to increasing demand for early cancer detection solutions. The Middle East shows higher adoption of advanced biopsy systems, while Africa is experiencing gradual growth due to improving access to diagnostic services. Approximately 40% of healthcare facilities in emerging African markets are upgrading diagnostic capabilities to support minimally invasive procedures. The Biopsy Needles Market Analysis indicates that government healthcare modernization programs, increasing private healthcare investments, and growing awareness about preventive diagnosis are creating new market opportunities.

List of Key Biopsy Needles Market Companies

• Medtronic
• BD Medical
• Boston Scientific
• Smith Medical
• Argon Medical Devices
• Novo Nordisk
• Terumo Corporation
• NIPRO Medical
• B. Braun Melsungen AG
• Medsurg
• TSK
• Hamilton Syringes & Needles
• Hi-Tech Medicare Devices

Top Two Companies with Highest Share

• Medtronic: Holds approximately 15% share in the global Biopsy Needles Market due to strong adoption of advanced biopsy systems, broad medical device capabilities, and high presence across hospitals and diagnostic centers.
• BD Medical: Accounts for nearly 13% share, supported by extensive biopsy device offerings, strong healthcare provider adoption, and continuous innovation in precision tissue sampling technologies.

Investment Analysis and Opportunities

The Biopsy Needles Market Investment Analysis highlights increasing opportunities driven by rising demand for early disease detection, minimally invasive procedures, and advanced diagnostic technologies. More than 65% of healthcare providers are focusing on upgrading biopsy equipment with improved accuracy and patient safety features. Investments are increasingly directed toward automated biopsy systems, disposable needle technologies, and imaging-compatible devices. Approximately 55% of manufacturers are expanding research and development activities to introduce advanced biopsy solutions with enhanced precision and reduced procedural complications. Growing adoption of personalized medicine is creating additional investment opportunities, as more than 60% of oncology diagnostic centers are prioritizing high-quality tissue sampling technologies.

Healthcare infrastructure expansion in emerging markets is providing significant opportunities for Biopsy Needles Market participants. Around 45% of hospitals in developing regions are increasing investments in diagnostic capabilities, creating demand for affordable and efficient biopsy devices. Private healthcare facilities and specialty clinics are also contributing to market expansion, with nearly 50% of new diagnostic centers incorporating minimally invasive biopsy procedures. Companies investing in lightweight designs, automated mechanisms, and disposable products are positioned to address changing healthcare requirements. Strategic partnerships, product innovation, and expansion into underpenetrated regions represent key investment opportunities as global demand for accurate biopsy procedures continues to increase.

New Products Development

New product development in the Biopsy Needles Market is focused on improving accuracy, reducing patient discomfort, and enhancing procedural efficiency. Manufacturers are introducing advanced biopsy needles with automated deployment systems, improved cutting mechanisms, and better imaging compatibility. Approximately 50% of new biopsy device developments emphasize precision sampling and reduced tissue damage. Disposable biopsy needle innovations are gaining attention, with nearly 55% of healthcare providers showing preference for single-use solutions due to infection prevention benefits. Companies are also developing ergonomic designs that improve handling efficiency and support faster diagnostic procedures.

Technological advancements are encouraging the development of next-generation biopsy systems integrated with advanced imaging platforms and digital healthcare solutions. More than 45% of product development initiatives focus on compatibility with ultrasound, CT, and MRI-guided procedures. Automated biopsy technologies are being enhanced to provide consistent sample quality, with approximately 60% of healthcare professionals considering accuracy improvement a major purchasing factor. Emerging product innovations include smaller needle designs, improved sample collection mechanisms, and enhanced safety features. Continuous development of advanced biopsy solutions is helping healthcare providers improve diagnostic outcomes while meeting increasing demand for minimally invasive procedures.

Five Recent Developments

• Medtronic Introduced Advanced Biopsy Solutions: In 2024, Medtronic focused on improving biopsy device performance through enhanced needle designs and procedural efficiency features. The company emphasized precision sampling technologies, with more than 60% of product improvement efforts directed toward accuracy, patient safety, and compatibility with advanced diagnostic workflows.

• BD Medical Expanded Precision Biopsy Technologies: In 2024, BD Medical strengthened its biopsy product portfolio by focusing on improved tissue collection mechanisms and disposable solutions. Approximately 55% of healthcare professionals showed increased preference for safer single-use biopsy devices, supporting the company’s development strategies in minimally invasive diagnostic procedures.

• Boston Scientific Enhanced Diagnostic Device Innovations: In 2024, Boston Scientific advanced biopsy-related technologies with emphasis on improved clinical usability and diagnostic accuracy. Around 50% of new product development initiatives focused on enhancing physician control, reducing procedure complexity, and supporting image-guided biopsy applications across oncology and specialty healthcare segments.

• Argon Medical Devices Improved Biopsy Needle Portfolio: In 2024, Argon Medical Devices introduced improvements in biopsy needle design focused on reliability and ease of use. Nearly 45% of product enhancements targeted better sample quality, reduced procedural challenges, and increased adoption among hospitals, clinics, and ambulatory diagnostic facilities.

• Terumo Corporation Advanced Minimally Invasive Technologies: In 2024, Terumo Corporation continued developing advanced medical device solutions supporting biopsy procedures. Approximately 50% of its innovation focus involved improving precision, safety features, and compatibility with modern imaging systems to address increasing demand for efficient tissue sampling procedures.

Report Coverage Of Biopsy Needles Market

The Biopsy Needles Market Report Coverage provides a detailed assessment of market performance, technology adoption, application trends, regional analysis, competitive landscape, and future opportunities. The report evaluates major product categories, including fully automatic and semi-automatic biopsy needles, which together represent nearly 100% of global market segmentation. The coverage analyzes key applications across hospitals, clinics, ambulatory surgical centers, and specialized diagnostic facilities. Hospitals account for approximately 60% of biopsy needle usage due to high patient volumes and availability of advanced imaging infrastructure. The report also highlights that oncology-related procedures contribute more than 60% of overall biopsy needle demand globally.

The Biopsy Needles Market Analysis covers regional performance across North America, Europe, Asia-Pacific, and Middle East & Africa. North America contributes nearly 40% of global market share, followed by Europe with approximately 30%, Asia-Pacific with around 22%, and Middle East & Africa with nearly 8%. The report evaluates market drivers such as increasing cancer screening programs, rising adoption of minimally invasive procedures, and advancements in imaging-guided biopsy technologies. It also examines challenges including regulatory requirements, product costs, and healthcare accessibility issues. Competitive analysis includes leading manufacturers, product innovations, and strategic developments, with more than 50% of companies focusing on automated systems, disposable technologies, and improved diagnostic accuracy. The coverage provides insights into investment opportunities, product development trends, and evolving healthcare requirements influencing the Biopsy Needles Market Outlook.